Traded Apr 23 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Traded Mar 26, 2026 · Filed Mar 28, 2026
The CEO of United Therapeutics sold $84K of United Therapeutics shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$84,421
Shares × reported transaction price
29 days after results of Feb 25, 2026, 41 days before results of May 6, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −4.9% | +4.3% | −9.2% |
| 30 days | −2.9% | +12.6% | −15.5% |
| 90 days | −7.4% | +17.3% | −24.6% |
| 180 days | −17.5% | +21.1% | −38.6% |
Past results only. Not a forecast.
Traded Apr 23 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
James Edgemond (CFO AND TREASURER) sold ~$159K of United Therapeutics
Scheduled in advanceJames Edgemond (CFO AND TREASURER) sold ~$616K of United Therapeutics
Scheduled in advance